Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Channing J. Der

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7751-2747; OpenAlex author ID A5064063895, A5127591535; NIH RePORTER profile ID 1860326. Sources: OpenAlex.

Their work

Papers
41 (first author 3, last author 15)
Trials
0
Grants
8
Labs led
1
Collaborators
186
Papers, trials and grants by year

2012: 1 grant · 2013: none · 2014: 2 papers · 2015: 1 grant · 2016: 2 papers · 2017: 1 paper, 1 grant · 2018: 1 paper, 1 grant · 2019: 3 papers, 1 grant · 2020: 3 papers, 1 grant · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers, 1 grant · 2025: 9 papers · 2026: 8 papers, 1 grant

Papers 41

  1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Last author DOI 10.1016/j.celrep.2026.117627↗
  2. Advances in RAS Therapeutics for Pancreatic Cancer. Co-author DOI 10.1056/nejme2600517↗
  3. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  4. KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1984↗
  5. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  6. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  7. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630↗
  8. Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer. Co-author DOI 10.1172/jci191370↗
  9. TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. Co-author DOI 10.1093/narcan/zcaf009↗
  10. TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress Co-author DOI 10.1101/2025.01.26.634889↗
  11. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Last author DOI 10.1126/scisignal.adu7145↗
  12. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
  13. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  14. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Last author DOI 10.1158/0008-5472.can-25-1507↗
  15. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  16. Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance Last author DOI 10.64898/2025.12.01.691471↗
  17. p53 and YAP/TAZ-TEAD activities determine metaplastic heterogeneity in pancreatic cancer Co-author DOI 10.64898/2025.12.11.693520↗
  18. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  19. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  20. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac237↗
  21. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-22-0391↗
  22. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Co-author DOI 10.18632/genesandcancer.231↗
  23. KRAS G12R-Independent Macropinocytosis in Pancreatic Cancer. First author DOI 10.1007/978-3-030-94004-1_11↗
  24. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Last author DOI 10.1016/bs.acr.2021.07.008↗
  25. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  26. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Last author DOI 10.1016/j.celrep.2021.109291↗
  27. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Last author DOI 10.1016/j.celrep.2021.110060↗
  28. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Last author DOI 10.1016/j.jbc.2021.101335↗
  29. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  30. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  31. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Last author DOI 10.1038/s41591-020-0947-8↗
  32. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-19-1006↗
  33. Blocking autophagy to starve pancreatic cancer. First author DOI 10.1038/s41580-019-0120-8↗
  34. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Last author DOI 10.1038/s41591-019-0368-8↗
  35. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Last author DOI 10.1126/scisignal.aav7259↗
  36. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. First author DOI 10.1101/cshperspect.a031435↗
  37. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. Co-author DOI 10.1371/journal.pone.0174863↗
  38. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Last author DOI 10.1016/j.ccell.2015.11.011↗
  39. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Co-author DOI 10.3390/cancers8040045↗
  40. KRAS: feeding pancreatic cancer proliferation. Last author DOI 10.1016/j.tibs.2013.12.004↗
  41. Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Co-author DOI 10.1158/1535-7163.mct-12-1232↗

Grants 8

  1. SToP Cancer SPORE: Administrative Core A P50CA257911↗
  2. Targeting undruggable RAS for cancer treatment R35CA232113↗
  3. Project 3: Mechanisms and therapeutic targeting of NRAS in melanoma P01CA203657↗
  4. Identification of synthetic lethal interactors in pancreatic cancer U01CA199235↗
  5. Mechanisms of PAK1 activation, signaling and tumor resistance R01CA175747↗
  6. Biological Activity of Ras Oncogenes R01CA042978↗
  7. ERK inhibitor resistance and ERK isoform-dependent growth in pancreatic cancer R21CA179193↗
  8. Genetic dissection and inhibitor targeting of Rac signaling in pancreatic cancer. R21CA161494↗

Closest collaborators

The 25 strongest of 186 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adrienne D. Cox · 18 shared papers, 2 shared grants, 2016–2026 · strength 3.27
  2. Kirsten L. Bryant · 18 shared papers, 2014–2026 · strength 2.49
  3. Clint A. Stalnecker · 15 shared papers, 2019–2026 · strength 2.36
  4. G. Aaron Hobbs · 10 shared papers, 2019–2026 · strength 1.52
  5. Jen Jen Yeh · 4 shared papers, 1 shared grant, 2014–2026 · strength 1.46
  6. Andrew M. Waters · 10 shared papers, 2018–2026 · strength 1.29
  7. Craig M. Goodwin · 9 shared papers, 2020–2026 · strength 1.27
  8. Jennifer E. Klomp · 10 shared papers, 2019–2026 · strength 1.18
  9. Mariaelena Pierobon · 10 shared papers, 2016–2025 · strength 1.08
  10. A. Cole Edwards · 6 shared papers, 2021–2026 · strength 1.05
  11. J. Nathaniel Diehl · 9 shared papers, 2019–2026 · strength 1.05
  12. Kristina Drizyte‐Miller · 6 shared papers, 2021–2025 · strength 0.99
  13. Bjoern Papke · 9 shared papers, 2019–2026 · strength 0.95
  14. Lee M. Graves · 7 shared papers, 2017–2026 · strength 0.92
  15. Emanuel F. Petricoin · 8 shared papers, 2016–2025 · strength 0.79
  16. Andrew J. Aguirre · 6 shared papers, 2020–2026 · strength 0.79
  17. Priya S. Hibshman · 5 shared papers, 2021–2026 · strength 0.74
  18. Emanuel F. Petricoin · 4 shared papers, 2023–2025 · strength 0.69
  19. Alina Cornelia Iuga · 1 shared grant, 2026 · strength 0.67
  20. Michael R Kosorok · 1 shared grant, 2026 · strength 0.67
  21. Gianpietro Dotti · 1 shared grant, 2026 · strength 0.67
  22. Jonathan S. Serody · 1 shared grant, 2026 · strength 0.67
  23. ALBERT Sidney BALDWIN · 1 shared grant, 2026 · strength 0.67
  24. Cyrus Vaziri · 3 shared papers, 2023–2025 · strength 0.65
  25. John P. Morris · 3 shared papers, 2020–2025 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.